Baker Bros. Advisors Boosts Stake in Vanda Pharmaceuticals Inc. (VNDA)

Page 1 of 2

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)In the hedge fund world, Julian Baker and Felix Baker’s Baker Bros. Advisors reported a purchase of 2,028,789 shares in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) in a 13G filing with the Securities and Exchange Commission. Altogether the position in Vanda Pharmaceuticals contains 3,966,179 shares and is worth about $47.3 million, at the current price of company’s stock. In this way, the stake held by Baker Bros. in Vanda Pharmaceuticals represents 14% of the company.

On the whole, 13G filings reveal the intentions of passive investors. These members of the smart money aren’t privy to an equal level of coverage as their activits peers, but passive managers should be watched in a similar light. This is why, it’s very beneficial for retail investors to understand HFM’s latest play into Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).

Despite that fact that most shareholders pay attention to a wide range of equity-based metrics, there’s one that should be watched more closely: aggregate hedge fund sentiment. At Insider Monkey, empirical studies have demonstrated that piggybackers who copy specific hedge fund activity can outbeat their index-focused peers by as much as 18 percentage points per year. (See the details about our strategy here)

While speaking about Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), we can mention that 10 other “hedgies” were invested in Company, in the latest round of 13F filings. Among them we can mention Jean-Marie Eveillard’s First Eagle Investment Management, which holds about 1.9 million shares valued at almost $7.5 million. Palo Alto Investors managed by William Leland Edwards owns around 1.7 million shares, worth some $6.9 million and Jim Simons Renaissance Technologies has in its equity portfolio almost 54,000 shares, worth $212,000.

Also, just as important, we must note some other equities in Baker Bros.’ 13F portfolio in addition to Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).

As follows, among them are XOMA Corp (NASDAQ:XOMA), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Genomic Health, Inc. (NASDAQ:GHDX) and they are discussed in more detail on the following page.

Page 1 of 2